Walleye Capital’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,600
Closed -$91.3K 5006
2025
Q4
$91.3K Buy
+5,600
New +$84.6K ﹤0.01% 3906
2025
Q2
Sell
-500
Closed -$4.37K 5056
2025
Q1
$4.37K Sell
500
-2,800
-85% -$35.3K ﹤0.01% 4107
2024
Q4
$47.4K Sell
3,300
-17,200
-84% -$271K ﹤0.01% 4372
2024
Q3
$463K Sell
20,500
-7,200
-26% -$149K ﹤0.01% 3367
2024
Q2
$539K Buy
27,700
+25,600
+1,219% +$670K ﹤0.01% 3443
2024
Q1
$78.8K Sell
2,100
-19,400
-90% -$852K ﹤0.01% 4507
2023
Q4
$1.2M Sell
21,500
-17,400
-45% -$757K ﹤0.01% 2204
2023
Q3
$1.6M Buy
38,900
+20,500
+111% +$1.07M ﹤0.01% 1896
2023
Q2
$1.03M Buy
18,400
+16,700
+982% +$904K ﹤0.01% 1831
2023
Q1
$94.8K Buy
1,700
+300
+21% +$14K ﹤0.01% 2961
2022
Q4
$51K Buy
+1,400
New +$45.8K ﹤0.01% 2516

Other funds holding TXG

Walleye Capital's TXG Position: Q1 2026 in Review

Walleye Capital sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 1,577 shares — an estimated $25.7K sold.

Walleye Capital first reported a position in TXG in Q2 2020 and held it in 13 quarters. The position peaked at $4.19M in Q4 2024. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Walleye Capital reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1,577 10x Genomics shares in Q1 2026, an estimated $25.7K.
  • Walleye Capital first reported a position in 10x Genomics in Q2 2020 and held it in 13 quarters.
  • Walleye Capital's 10x Genomics position peaked at $4.19M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.